SLC34A2 and ovarian cancer: In the situation of using alpha emitting radionuclides i.e. targeted alpha therapy (TAT) for ovarian cancer, recently also explored for other antigenic targets than NaPi2b, a solution containing antibodies labeled with α-particles emitting radionuclide is injected locally into the peritoneal cavity [16].